# Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency

> **NCT00330668** · PHASE3 · TERMINATED · sponsor: **Ipsen** · enrollment: 114 (actual)

## Conditions studied

- Growth Disorders

## Interventions

- **DRUG:** rh IGF-1 (mecasermin)

## Key facts

- **NCT ID:** NCT00330668
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-11
- **Primary completion:** 2010-02
- **Final completion:** 2010-03
- **Target enrollment:** 114 (ACTUAL)
- **Why stopped:** Unacceptable frequency of hypoglycemia observed at and above 200 ug/kg/day
- **Last updated:** 2020-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00330668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00330668, "Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00330668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*